PDGFRB and hepatocellular carcinoma: Lenvatinib, another anti-angiogenic drug inhibiting VEGFR, fibroblast growth factor (FGF), and PDGFR with higher potency than sorafenib, is also used for unresectable HCC and showed an improvement in overall survival of the patients which was comparable to sorafenib [131].